Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication

  title={Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication},
  author={Paolo Gresele and Rino Migliacci and A. Procacci and Paola De Monte and Erminio Bonizzoni},
  journal={Thrombosis and Haemostasis},
  pages={444 - 450}
Summary Ischemia/reperfusion damage evokes systemic inflammation and endothelial dysfunction in patients with intermittent claudication. We compared the effects of aspirin with those of a nitric oxide-donating aspirin in preventing the acute, systemic endothelial dysfunction provoked by exercise-induced ischemia of the lower limbs in patients with intermittent claudication. In a prospective, randomized, single-blind, parallel-groups trial among 44 patients with intermittent claudication we… 

Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent

Acute hyperglycemia-induced enhancement of platelet activation is resistant to aspirin; a NO-donating agent suppresses it, and therapeutic approaches aiming at a wider platelet inhibitory action than that exerted by aspirin may prove useful in patients with type 2 diabetes.

Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking in rats

Cilostazol (but not aspirin) may prevent the smoking-induced impairment of endothelium-dependent vasodilation in cerebral pial arterioles.

Potential identification of a claudicant group vulnerable to acute kidney injury

The mechanism by which the phenotypically distinct sub-group of patients with intermittent claudication who experience a NAG/Cr rise involves complex interactions between systemic oxidative stress and endothelial function requires further investigation.

Nitric Oxide-Releasing Aspirin in Atherothrombosis: A Remarkable Improvement of an Old Drug

A newly developed drug, the nitric oxide (NO)releasing aspirin, provides new hope for eliminating the side effects of the classic aspirin, and may replace the classic and well studied aspirin, in the fight against atherothrombosis.

Walking-induced endothelial dysfunction predicts ischemic cardiovascular events in patients with intermittent claudication

Maximal exercise-induced endothelial dysfunction is predictive of cardiovascular events in patients with IC, and a post-exercise reduction of brachial FMD > 1.3% was predictive for cardiovascular events.

Prevention of transient endothelial dysfunction in acute exercise: A friendly fire?

A head-to-head comparison between aspirin with those of the aspirin dervivative NCX-4016 under the conditions of acute exercise in cardiovascular patients appears to be an exciting approach and extends numerous previous studies on this new and potentially useful drug.

Nitric oxide-donating statins: a new concept to boost the lipid-independent effects.

This editorial refers to ‘Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis’ by S. Momi et al .,



Nitric Oxide–Releasing Aspirin Derivative, NCX 4016, Promotes Reparative Angiogenesis and Prevents Apoptosis and Oxidative Stress in a Mouse Model of Peripheral Ischemia

Pretreatment with the new oral NO-releasing aspirin derivative stimulates reparative angiogenesis and prevents apoptosis and oxidative stress, thereby alleviating the consequences of supervening arterial occlusion.

Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.

In phase II studies, NCX 4016 had favorable effects on effort-induced endothelial dysfunction in intermittent claudication and on platelet-activation parameters elicited by short-term hyperglycemia in type II diabetics, and in patients with type II diabetes the effects of NCX4016 on microalbuminuria and on some hemodynamic parameters were promising.

L-arginine protects from ischemia-reperfusion-induced endothelial dysfunction in humans in vivo.

It is demonstrated that the NO substrate l-arginine significantly attenuates ischemia-reperfusion-induced endothelial dysfunction in humans in vivo, suggesting that l- arginine may be useful as a therapeutic agent in the treatment of ischemIA-rePerfusion injury in humans.

Exercise training reduces the acute inflammatory response associated with claudication.

This study for the first time demonstrates that the exercise training of claudicants is beneficial, not only in terms of improving their walking distance, but also by decreasing the injurious effects of IRI that occur during claudication.

Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study.

The concept that addition of an NO-donating moiety to aspirin results in a new chemical entity that maintains cyclooxygenase-1 and platelet inhibitory activity while nearly avoiding gastrointestinal damage is proven.

Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans

S typhi vaccine generates a mild inflammatory reaction associated with temporary but profound dysfunction of the arterial endothelium in both resistance and conduit vessels to both physical and pharmacological dilator stimuli, which might explain the association between infection and inflammation and the enhanced risk of an acute cardiovascular event.

Nonsteroidal Antiinflammatory Drugs Aggravate Acute Myocardial Ischemia in the Perfused Rabbit Heart: A Role for Prostacyclin

The present data suggests that the deleterious effect of nonsteroidal antiinflammatory drugs in low flow myocardial ischemia and reperfusion damage may be associated with removal of PGI2 and PGE2 from ischemic myocardium.

Functional and Biochemical Analysis of Endothelial (Dys)function and NO/cGMP Signaling in Human Blood Vessels With and Without Nitroglycerin Pretreatment

It is concluded that long-term NTG treatment induces endothelial dysfunction and impaired vascular NO/cGMP signaling in humans, which can be monitored by measuring P-VASP levels.